Feladilimab

DB16415InvestigationalProtein Based Therapies

Feladilimab is under investigation in clinical trial NCT04128696 (Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma).

Mechanism: Pharmacologically active on Inducible T-cell costimulator
Curator reviewed
Code names: GSK-3359609

Resolves to

Compound

UNIIOUP4QB2A3R

Targets

Q9Y6W8ICOS

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Feladilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account